GenomeWeb Feature: Tools for Point-of-Care MDx Available, but Challenges Still Loom | GenomeWeb

This article has been updated from a previous version to correct the names of an individual and research institution.

The point-of-care molecular diagnostics market is "a race to the bottom" in terms of cost and turnaround time, and it is being fueled by rapid innovation in microfluidics, miniaturization, and nucleic acid amplification, detection, and sequencing technologies, according to industry insiders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.